Thomas Quentin Dominique, Basse Clémence, Belaroussi Yaniss, Beaucaire-Danel Sophie, Daniel Catherine, Quantin Xavier, Girard Nicolas
Department of Medical Oncology, Montpellier Cancer Institute, Montpellier (ICM), France.
Oncogenic Pathways in Lung Cancer, Montpellier Cancer Research Institute (IRCM), University of Montpellier (UM), Montpellier, France.
JTO Clin Res Rep. 2022 May 6;3(6):100333. doi: 10.1016/j.jtocrr.2022.100333. eCollection 2022 Jun.
Telehealth is taking an increasingly important part of medicine. This practice change is being accelerated by the pandemic linked to coronavirus disease 2019. Oncology is a medical specialty for which this paradigm shift is particularly relevant.
We developed a survey aiming at evaluating the use of teleconsultation by physicians managing patients with lung cancer in France. The survey was available online from December 15, 2020, to February 10, 2021.
Answers were obtained from 142 clinicians (73.9% pneumologists, 18.3% medical oncologists, and 7.7% with another specialty), 129 (90.8%) of whom had already performed teleconsultation. Among those, 123 (95.3%) started after the coronavirus disease 2019 pandemic. In addition, 72.9% had a moderate usage of this tool (<10 teleconsultations/mo). The frequency of clinicians never using teleconsultation was higher in private practices ( = 0.029). The two clinical situations for which teleconsultation was frequently used were visits during treatment without imaging assessment (53.5%) and post-treatment surveillance (80.3%). Depending on the type of treatment received, the frequency of teleconsultation was variable. Lung cancer subtype also affected the clinician's practice. Indeed, 47.2% never proposed this tool for SCLC. Teleconsultation was considered to be of no contribution, a moderate contribution, a significant contribution, or a revolution of the clinical practice for 14.1%, 66.2%, 10.6%, and 2.1% of the respondents, respectively. The participants expected to decrease, stabilize, or increase their teleconsultation activity in 18.3%, 52.8%, and 23.2% of the cases, respectively.
Most thoracic oncologists in France are using teleconsultation, mostly as an additional tool that should not replace the doctor-patient in-person relationship.
远程医疗在医学领域正发挥着越来越重要的作用。与2019年冠状病毒病相关的疫情加速了这种实践变革。肿瘤学是一个与这种范式转变特别相关的医学专业。
我们开展了一项调查,旨在评估法国肺癌患者管理医生对远程会诊的使用情况。该调查于2020年12月15日至2021年2月10日在线进行。
共获得142名临床医生的回复(73.9%为肺病专家,18.3%为肿瘤内科医生,7.7%为其他专业),其中129名(90.8%)已经进行过远程会诊。在这些人中,123名(95.3%)是在2019年冠状病毒病疫情之后开始的。此外,72.9%的人对该工具的使用频率适中(每月<10次远程会诊)。私人诊所中从未使用过远程会诊的临床医生比例更高(P = 0.029)。经常使用远程会诊的两种临床情况是治疗期间无影像评估的就诊(53.5%)和治疗后监测(80.3%)。根据接受的治疗类型,远程会诊的频率各不相同。肺癌亚型也影响临床医生的实践。实际上,47.2%的人从未为小细胞肺癌患者推荐过这种工具。分别有14.1%、66.2%、10.6%和2.1%的受访者认为远程会诊对临床实践无贡献、有一定贡献、有显著贡献或具有变革性。在18.3%、52.8%和23.2%的情况下,参与者预计会减少、稳定或增加他们的远程会诊活动。
法国大多数胸科肿瘤学家正在使用远程会诊,主要将其作为一种辅助工具,不应取代医患面对面的关系。